DISC MEDICINE INC. - COMMON STOCK

Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates

02 11 2023 09:00:00 提供 Nasdaq GlobeNewswire

Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce

23 10 2023 09:15:00 提供 Nasdaq GlobeNewswire

Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

03 10 2023 08:30:00 提供 Nasdaq GlobeNewswire

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera

20 9 2023 16:30:00 提供 Nasdaq GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

30 8 2023 16:15:00 提供 Nasdaq GlobeNewswire

Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update

11 8 2023 08:00:00 提供 Nasdaq GlobeNewswire

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)

27 7 2023 09:00:01 提供 Nasdaq GlobeNewswire

Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

22 6 2023 16:15:00 提供 Nasdaq GlobeNewswire

Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

13 6 2023 22:39:30 提供 Nasdaq GlobeNewswire

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

12 6 2023 16:00:00 提供 Nasdaq GlobeNewswire

Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

09 6 2023 07:00:00 提供 Nasdaq GlobeNewswire

Disc Medicine to Participate in the Jefferies Healthcare Conference

31 5 2023 16:00:00 提供 Nasdaq GlobeNewswire

Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update

15 5 2023 07:00:00 提供 Nasdaq GlobeNewswire

Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

11 5 2023 10:15:00 提供 Nasdaq GlobeNewswire

Disc Medicine to Participate in H.C. Wainwright BioConnect Investor Conference

21 4 2023 08:30:00 提供 Nasdaq GlobeNewswire

Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)

13 4 2023 11:00:00 提供 Nasdaq GlobeNewswire

Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update

31 3 2023 07:00:00 提供 Nasdaq GlobeNewswire

Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)

21 3 2023 07:00:00 提供 Nasdaq GlobeNewswire

Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

16 2 2023 08:00:56 提供 Nasdaq GlobeNewswire

Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs

14 2 2023 06:30:00 提供 Nasdaq GlobeNewswire